Found: 211
Select item for more details and to access through your institution.
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 9, p. 1746, doi. 10.1002/ajh.27382
- By:
- Publication type:
- Article
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01121-8
- By:
- Publication type:
- Article
Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-69408-1
- By:
- Publication type:
- Article
Insight into the mechanism of CD34<sup>+</sup> cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1439, doi. 10.1111/bjh.19141
- By:
- Publication type:
- Article
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 3, p. 981, doi. 10.1007/s00277-023-05572-0
- By:
- Publication type:
- Article
Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis.
- Published in:
- Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 2024, v. 168, n. 1, p. 50, doi. 10.5507/bp.2023.023
- By:
- Publication type:
- Article
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 2, p. e40, doi. 10.1016/j.clml.2023.10.003
- By:
- Publication type:
- Article
Thoracoscopic epicardial ablation of atrial fibrillation: Safety, efficacy, single center experience.
- Published in:
- Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 2023, v. 167, n. 4, p. 362, doi. 10.5507/bp.2022.041
- By:
- Publication type:
- Article
NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 23, p. 2748, doi. 10.3390/cells12232748
- By:
- Publication type:
- Article
An economic evaluation of the effectiveness of telemedicine in hematooncology.
- Published in:
- PLoS ONE, 2023, v. 18, n. 11, p. 1, doi. 10.1371/journal.pone.0291143
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 687, doi. 10.1016/j.clml.2023.05.004
- By:
- Publication type:
- Article
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1501, doi. 10.1007/s00277-023-05188-4
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5623, doi. 10.3390/ijms24065623
- By:
- Publication type:
- Article
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04041-6
- By:
- Publication type:
- Article
SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA.
- Published in:
- Acta Haematologica Polonica, 2023, v. 54, n. 2, p. 82, doi. 10.5603/AHP.a2023.0016
- By:
- Publication type:
- Article
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. e171, doi. 10.1016/j.clml.2022.12.003
- By:
- Publication type:
- Article
Novel Local "Off-the-Shelf" Immunotherapy for the Treatment of Myeloma Bone Disease.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 3, p. 448, doi. 10.3390/cells12030448
- By:
- Publication type:
- Article
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 2, p. 145, doi. 10.1016/j.clml.2022.11.001
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. E15, doi. 10.1002/ajh.26602
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00791-0
- By:
- Publication type:
- Article
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00789-8
- By:
- Publication type:
- Article
The Benefit of Telemonitoring in the Prevention of Septic Shock in a Patient with Aggressive Non-Hodgkin's Lymphoma.
- Published in:
- Case Reports in Oncology, 2023, v. 16, n. 1, p. 149, doi. 10.1159/000526930
- By:
- Publication type:
- Article
Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 23, p. 14765, doi. 10.3390/ijms232314765
- By:
- Publication type:
- Article
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34654-2
- By:
- Publication type:
- Article
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
- Published in:
- Neoplasma, 2022, v. 69, n. 6, p. 1474, doi. 10.4149/neo_2022_220813N827
- By:
- Publication type:
- Article
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 5165, doi. 10.3390/cancers14205165
- By:
- Publication type:
- Article
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
- Published in:
- Biomedicines, 2022, v. 10, n. 10, p. N.PAG, doi. 10.3390/biomedicines10102535
- By:
- Publication type:
- Article
Corrigendum to "P-196: Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas: IKEMA Subgroup Analysis, Clinical Lymphoma Myeloma and Leukemia".
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 10, p. 785, doi. 10.1016/j.clml.2022.06.009
- By:
- Publication type:
- Article
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 6, p. 988, doi. 10.1111/bjh.18233
- By:
- Publication type:
- Article
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 802, doi. 10.1002/ajh.26529
- By:
- Publication type:
- Article
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 3, p. 302, doi. 10.1111/bjh.18073
- By:
- Publication type:
- Article
Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine.
- Published in:
- Cancer Management & Research, 2022, v. 14, p. 1655, doi. 10.2147/CMAR.S348923
- By:
- Publication type:
- Article
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 280, doi. 10.1002/hon.2974
- By:
- Publication type:
- Article
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
- By:
- Publication type:
- Article
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 4, p. 954, doi. 10.1111/bjh.17925
- By:
- Publication type:
- Article
Natural Killer Cells in the Malignant Niche of Multiple Myeloma.
- Published in:
- Frontiers in Immunology, 2022, v. 12, p. 1, doi. 10.3389/fimmu.2021.816499
- By:
- Publication type:
- Article
Praktické aspekty terapie CAR-T lymfocyty.
- Published in:
- Journal of the Czech & Slovak Societies for Oncology / Klinická Onkologie, 2022, v. 35, n. 1, p. 44
- By:
- Publication type:
- Article
Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network.
- Published in:
- Kompass Onkologie, 2022, v. 9, n. 1, p. 3, doi. 10.1159/000522451
- By:
- Publication type:
- Article
GM3 Ganglioside Linked to Neurofibrillary Pathology in a Transgenic Rat Model for Tauopathy.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 22, p. 12581, doi. 10.3390/ijms222212581
- By:
- Publication type:
- Article
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 21, p. 11470, doi. 10.3390/ijms222111470
- By:
- Publication type:
- Article
OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S22, doi. 10.1016/S2152-2650(21)02109-1
- By:
- Publication type:
- Article
OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S29, doi. 10.1016/S2152-2650(21)02120-0
- By:
- Publication type:
- Article
P-020: Altered mRNA splicing identifies novel biomarkers and therapeutic targets in AL (Amyloid light-chain) Amyloidosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S50, doi. 10.1016/S2152-2650(21)02154-6
- By:
- Publication type:
- Article
P-046: B cell transcriptional coactivator POU2AF1 (BOB-1) modulates the protein synthesis and offers a potential vulnerability in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S63, doi. 10.1016/S2152-2650(21)02180-7
- By:
- Publication type:
- Article
P-077: Bone marrow microenvironment analysis of exosomal microRNAs in multiple myeloma, extramedullary disease and plasma cell leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S81, doi. 10.1016/S2152-2650(21)02211-4
- By:
- Publication type:
- Article